ArticleNPJ breast cancer2022
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study.
Article in NPJ breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Distinct epigenetic alterations and accelerated mitotic aging define second primary breast cancers.Scientific reports · 2026Article
- Impact of Multicancer Screening on Late-Stage Cancer at Diagnosis in Breast Cancer Survivors: A Modeling Study.JCO precision oncology · 2026Article
- Prediction of overall survival in patients with hepatocellular carcinoma and second primary malignancies: a prognostic model based on the SEER database.Translational cancer research · 2026Article
- The risk of mortality from multiple primary cancers in colorectal cancer survivors: analysis of data from the South Australian Cancer Registry.Journal of cancer research and clinical oncology · 2025Article
- Patterns of Subsequent Cancer Incidence Over Time in Patients with Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Does chemotherapy improve survival outcomes in breast cancer survivors with secondary primary stage I non-small cell lung cancer? A real-world analysis using machine learning models.Frontiers in oncology · 2025Article
- Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors.JACC. CardioOncology · 2024Article
- Mammographic Breast Density at Breast Cancer Diagnosis and Breast Cancer-Specific Survival.Diagnostics (Basel, Switzerland) · 2024Article
- The contribution of second primary cancers to the mortality of patients with a first primary breast cancer.Breast cancer research and treatment · 2024Article
- Medical history of thyroid cancer does not impair prognosis in non-metastatic breast cancer patients: an analysis study based on SEER database and external cohort.Frontiers in oncology · 2024Article
- Association of metabolic syndrome conditions with risk of second primary uterine cancer in breast cancer survivors.Journal of cancer research and clinical oncology · 2023Article
- Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.JNCI cancer spectrum · 2023Article
- Impact of pre- and post-diagnosis physical activity on the mortality of patients with cancer: Results from the Health Examinees-G study in Korea.Cancer medicine · 2023Article
- Presence of Multi-Morbidities and Colorectal Cancer Screening Utilization among Breast Cancer Survivors.Cancers · 2023Article
- Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy.Journal of the National Cancer Institute · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited information exists about survival outcomes after second primary cancers (SPCs) among breast cancer survivors. Studies suggest that mortality after certain SPCs may be higher than mortality after first primary cancers (FPCs) of the same type. A cohort study was conducted among 63,424 US women using the Surveillance, Epidemiology, and End Results 18 database (2000-2016) to compare mortality after a SPC among breast cancer survivors to mortality among women after a FPC using Cox proportional hazard regression. Propensity scores were used to match survivors with SPCs to women with FPCs 1:1 based on cancer type and prognostic factors. During a median follow-up of 42 months, 11,532 cancer deaths occurred after SPCs among survivors compared to 9305 deaths after FPCs. Cumulative cancer mortality was 44.7% for survivors with SPCs and 35.2% for women with FPCs. Survivors with SPCs had higher risk of cancer death (hazard ratio (HR): 1.27, 95% CI: 1.23-1.30) and death overall (HR: 1.18, 95% CI: 1.15-1.21) than women with FPCs. Increased risk of cancer death after SPCs compared to FPCs was observed for cancer in breast, lung, colon and/or rectum, uterus, lymphoma, melanoma, thyroid, and leukemia. Estrogen receptor status and treatment of the prior breast cancer as well as time between prior breast cancer and SPC significantly modified the mortality difference between women with SPC and FPC. A more tailored approach to early detection and treatment could improve outcomes from second cancer in breast cancer survivors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.